Article info

Original research
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

Authors

  • Esther Redin IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, SpainCIBERONC, ISCIII, Madrid, SpainDepartment of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Irati Garmendia IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, SpainDepartment of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Teresa Lozano Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Diego Serrano IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, SpainDepartment of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Yaiza Senent IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Miriam Redrado IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Maria Villalba Department of Pathology, University Clinic of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Carlos E De Andrea Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, SpainDepartment of Pathology, University Clinic of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Francisco Exposito IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, SpainCIBERONC, ISCIII, Madrid, SpainDepartment of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Daniel Ajona IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, SpainCIBERONC, ISCIII, Madrid, SpainDepartment of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Sergio Ortiz-Espinosa IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, SpainDepartment of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Ana Remirez IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Cristina Bertolo IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, SpainCIBERONC, ISCIII, Madrid, Spain PubMed articlesGoogle scholar articles
  • Cristina Sainz IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Juana Garcia-Pedrero CIBERONC, ISCIII, Madrid, SpainDepartment of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, Oviedo, Spain PubMed articlesGoogle scholar articles
  • Ruben Pio IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, SpainCIBERONC, ISCIII, Madrid, SpainDepartment of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Juan Lasarte Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Jackeline Agorreta IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, SpainCIBERONC, ISCIII, Madrid, SpainDepartment of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Luis M Montuenga IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, SpainCIBERONC, ISCIII, Madrid, SpainDepartment of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Alfonso Calvo IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, SpainCIBERONC, ISCIII, Madrid, SpainDepartment of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Alfonso Calvo; acalvo{at}unav.es
View Full Text

Citation

Redin E, Garmendia I, Lozano T, et al
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

Publication history

  • Accepted January 12, 2021
  • First published March 3, 2021.
Online issue publication 
March 03, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.